{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:13:52Z","timestamp":1792178032896,"version":"4.4.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,1,30]],"date-time":"2013-01-30T00:00:00Z","timestamp":1359504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00702-013-0979-z","type":"journal-article","created":{"date-parts":[[2013,1,29]],"date-time":"2013-01-29T11:20:16Z","timestamp":1359458416000},"page":"689-694","source":"Crossref","is-referenced-by-count":27,"title":["The pharmacology of Tourette syndrome"],"prefix":"10.1007","volume":"120","author":[{"given":"Roji","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea E.","family":"Cavanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,30]]},"reference":[{"key":"979_CR1","unstructured":"American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed., text revision. American Psychiatric Association: Washington, DC"},{"key":"979_CR2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0361-9230(83)90192-2","volume":"11","author":"RL Borison","year":"1983","unstructured":"Borison RL, Ang L, Hamilton WJ, Diamond BI, Davis JM (1983) Treatment approaches in Gilles de la Tourette syndrome. Brain Res Bull 11:205\u2013208","journal-title":"Brain Res Bull"},{"key":"979_CR101","doi-asserted-by":"crossref","unstructured":"Cath DC, Hedderly T, Ludolph AG, Stern JS, Murphy T, Hartmann A, Czernecki V, Robertson MM, Martino D, Munchau A, Rizzo R, ESSTS Guidelines Group (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part I: assessment. Eur Child Adolesc Psychiatry 20:155\u2013171","DOI":"10.1007\/s00787-011-0164-6"},{"key":"979_CR3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1176\/appi.neuropsych.21.1.13","volume":"21","author":"AE Cavanna","year":"2009","unstructured":"Cavanna AE, Servo S, Monaco F, Robertson MM (2009) The behavioral spectrum of Gilles de la Tourette syndrome. J Neuropsychiatry Clin Neurosci 21:13\u201323","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"979_CR4","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/0269881111408462","volume":"26","author":"AE Cavanna","year":"2012","unstructured":"Cavanna AE, Selvini C, Termine C, Luoni C, Eddy CM, Rickards H (2012) Tolerability profile of aripiprazole in patients with Tourette syndrome. J Psychopharmacol 26:891\u2013895","journal-title":"J Psychopharmacol"},{"key":"979_CR5","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00004714-200202000-00006","volume":"22","author":"Y Dion","year":"2002","unstructured":"Dion Y, Annable L, Sandor P, Chouinard G (2002) Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 22:31\u201339","journal-title":"J Clin Psychopharmacol"},{"key":"979_CR6","first-page":"296","volume":"35","author":"I Drtilkova","year":"1994","unstructured":"Drtilkova I, Balastikova B, Lemanova H, Zak J (1994) Therapeutic effects of clonidine and clonazepam in children with tick syndrome. Homeostasis Health Dis 35:296","journal-title":"Homeostasis Health Dis"},{"key":"979_CR7","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1177\/1756285610390261","volume":"4","author":"CM Eddy","year":"2011","unstructured":"Eddy CM, Rickards HE, Cavanna AE (2011) Treatment strategies for tics in Tourette syndrome. Ther Adv Neurol Disord 4:25\u201345","journal-title":"Ther Adv Neurol Disord"},{"key":"979_CR100","unstructured":"Goetz CG (1992) Clonidine and clonazepam in Tourette syndrome. Adv Neurol 58:245\u2013251"},{"key":"979_CR8","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10072-011-0678-1","volume":"32","author":"M Gulisano","year":"2011","unstructured":"Gulisano M, Cal\u00ec PV, Cavanna AE, Eddy C, Rickards H, Rizzo R (2011) Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci 32:1213\u20131217","journal-title":"Neurol Sci"},{"key":"979_CR9","first-page":"23","volume":"27","author":"N Hassan","year":"2012","unstructured":"Hassan N, Cavanna AE (2012) The prognosis of Tourette syndrome: implications for clinical practice. Funct Neurol 27:23\u201327","journal-title":"Funct Neurol"},{"key":"979_CR10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/NDT.S12990","volume":"8","author":"D Huys","year":"2012","unstructured":"Huys D, Hardenacke K, Poppe P, Bartsch C, Baskin B, Kuhn J (2012) Update on the role of antipsychotics in the treatment of Tourette syndrome. Neuropsychiatr Dis Treat 8:95\u2013104","journal-title":"Neuropsychiatr Dis Treat"},{"key":"979_CR11","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","volume":"48","author":"J Jankovic","year":"1997","unstructured":"Jankovic J, Beach J (1997) Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 48:358\u2013362","journal-title":"Neurology"},{"key":"979_CR12","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","volume":"81","author":"J Jankovic","year":"2010","unstructured":"Jankovic J, Jimenez-Shahed J, Brown L (2010) A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry 81:70\u201373","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"979_CR13","first-page":"66","volume":"9","author":"WD Ji","year":"2005","unstructured":"Ji WD, Li Y, Li N, Guo BY (2005) Olanzapine for treatment of Tourette syndrome: a double-blind randomized controlled trial. Chinese J Clin Rehab 9:66\u201368","journal-title":"Chinese J Clin Rehab"},{"key":"979_CR14","first-page":"572","volume":"49","author":"ZS Liu","year":"2011","unstructured":"Liu ZS, Chen YH, Zhong YQ, Zou LP, Wang H, Sun D, Wang DB, Liao JX (2011) A multicentre controlled study on aripiprazole treatment for children with Tourette syndrome in China. Zhonghua Er Ke Za Zhi 49:572\u2013576","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"979_CR15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1176\/ajp.148.6.793","volume":"148","author":"BJ McConville","year":"1991","unstructured":"McConville BJ, Fogelson MH, Norman AB, Klykylo WM, Manderscheid PZ, Parker KW, Sanberg PR (1991) Nicotine potentiation of haloperidol in reducing tic frequency in Tourette\u2019s disorder. Am J Psychiatry 148:793\u2013794","journal-title":"Am J Psychiatry"},{"key":"979_CR17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1176\/ajp.156.3.495","volume":"156","author":"KR Muller-Vahl","year":"1999","unstructured":"Muller-Vahl KR, Schneider U, Kolbe H, Emrich HM (1999) Treatment of Tourette\u2019s syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156:495","journal-title":"Am J Psychiatry"},{"key":"979_CR18","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1055\/s-2002-25028","volume":"35","author":"KR Muller-Vahl","year":"2002","unstructured":"Muller-Vahl KR, Schneider U, Koblenz A, Jobges M, Kolbe H, Daldrup T, Emrich HM (2002) Treatment of Tourette\u2019s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57\u201361","journal-title":"Pharmacopsychiatry"},{"key":"979_CR19","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4088\/JCP.v64n0417","volume":"64","author":"KR Muller-Vahl","year":"2003","unstructured":"Muller-Vahl KR, Schneider U, Prevedel H, Theloe K, Kolbe H, Daldrup T, Emrich HM (2003a) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459\u2013465","journal-title":"J Clin Psychiatry"},{"key":"979_CR20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/sj.npp.1300047","volume":"28","author":"KR Muller-Vahl","year":"2003","unstructured":"Muller-Vahl KR, Prevedel H, Theloe K, Kolbe H, Emrich HM, Schneider U (2003b) Treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta 9-THC): no influence on neuropsychological performance. Neuropsychopharmacology 28:384\u2013388","journal-title":"Neuropsychopharmacology"},{"key":"979_CR102","doi-asserted-by":"crossref","unstructured":"Muller-Vahl KR, Cath DC, Cavanna AE, Dehning S, Porta M, Robertson MM, Visser-Vandewalle V, ESSTS Guidelines Group (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part IV: deep brain stimulation. Eur Child Adolesc Psychiatry 20:209\u2013217","DOI":"10.1007\/s00787-011-0166-4"},{"key":"979_CR21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1227\/NEU.0b013e3182535a00","volume":"71","author":"JCP Piedad","year":"2012","unstructured":"Piedad JCP, Rickards HE, Cavanna AE (2012) What patients with gilles de la tourette syndrome should be treated with deep brain stimulation and what is the best target? Neurosurgery 71:173\u2013192","journal-title":"Neurosurgery"},{"key":"979_CR22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00044011-200828070-00006","volume":"28","author":"M Porta","year":"2008","unstructured":"Porta M, Sassi M, Cavallazzi M, Fornari M, Brambilla A, Servello D (2008) Tourette\u2019s syndrome and the role of tetrabenazine: review and personal experience. Clin Drug Investig 28:443\u2013459","journal-title":"Clin Drug Investig"},{"key":"979_CR23","doi-asserted-by":"crossref","unstructured":"Pringsheim T, Marras C (2009) Pimozide for tics in Tourette\u2019s syndrome. Cochrane Database Syst Rev 2:CD006996","DOI":"10.1002\/14651858.CD006996.pub2"},{"key":"979_CR24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/070674371205700302","volume":"57","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P (2012) Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy. Can J Psychiatry 57:133\u2013143","journal-title":"Can J Psychiatry"},{"key":"979_CR25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.12968\/hmed.2011.72.2.100","volume":"72","author":"MM Robertson","year":"2011","unstructured":"Robertson MM (2011) Gilles de la Tourette syndrome: the complexities of phenotype and treatment. Br J Hosp Med 72:100\u2013107","journal-title":"Br J Hosp Med"},{"key":"979_CR26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00002826-199006000-00005","volume":"13","author":"MM Robertson","year":"1990","unstructured":"Robertson MM, Schneider V, Lees AJ (1990) Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropsychopharmacol 13:229\u2013235","journal-title":"Clin Neuropsychopharmacol"},{"key":"979_CR27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jpsychores.2009.07.010","volume":"67","author":"MM Robertson","year":"2009","unstructured":"Robertson MM, Eapen V, Cavanna AE (2009) The international prevalence, epidemiology and clinical phenomenology of Tourette syndrome: a cross-cultural perspective. J Psychosom Res 67:475\u2013483","journal-title":"J Psychosom Res"},{"key":"979_CR28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00787-011-0163-7","volume":"20","author":"V Roessner","year":"2011","unstructured":"Roessner V, Plessen KJ, Rothenberger A, Ludolph AG, Rizzo R, Skov L, Strand G, Stern JS, Termine C, Hoekstra PJ, ESSTS Guidelines Group (2011) European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatr 20:173\u2013196","journal-title":"Eur Child Adolesc Psychiatr"},{"key":"979_CR29","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1176\/ajp.154.8.1057","volume":"154","author":"FR Sallee","year":"1997","unstructured":"Sallee FR, Nesbitt L, Jackson C, Sine L, Sethuraman G (1997) Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette\u2019s disorder. Am J Psychiatr 154:1057\u20131062","journal-title":"Am J Psychiatr"},{"key":"979_CR30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00004714-199006000-00007","volume":"10","author":"P Sandor","year":"1990","unstructured":"Sandor P, Musisi S, Moldofsky H, Lang A (1990) Tourette syndrome: a follow-up study. J Clin Psychopharmacol 10:197\u2013199","journal-title":"J Clin Psychopharmacol"},{"key":"979_CR31","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/01.WNL.0000055434.39968.67","volume":"60","author":"L Scahill","year":"2003","unstructured":"Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS (2003) A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 60:1130\u20131135","journal-title":"Neurology"},{"key":"979_CR32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.nurx.2006.01.009","volume":"3","author":"L Scahill","year":"2006","unstructured":"Scahill L, Erenberg G, Berlin CM, Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA, Kurlan R, Lang A, Mink J, Murphy T, Zinner S, Walkup J, Tourette Syndrome Association Medical Advisory Board: Practice Committee (2006) Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 3:192\u2013206","journal-title":"NeuroRx"},{"key":"979_CR34","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/archpsyc.1983.01790100081011","volume":"40","author":"AK Shapiro","year":"1983","unstructured":"Shapiro AK, Shapiro E, Eisenkraft GJ (1983) Treatment of Gilles de la Tourette syndrome with clonidine and neuroleptics. Arch Gen Psychiatr 40:1235\u20131240","journal-title":"Arch Gen Psychiatr"},{"key":"979_CR35","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/archpsyc.1989.01810080052006","volume":"46","author":"E Shapiro","year":"1989","unstructured":"Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandell J, Nordlie J, Phillips RA (1989) Controlled study of haloperidol, pimozide, and placebo for the treatment of Gilles de la Tourette\u2019s syndrome. Arch Gen Psychiatr 46:722\u2013730","journal-title":"Arch Gen Psychiatr"},{"key":"979_CR36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1542\/peds.95.1.74","volume":"95","author":"HS Singer","year":"1995","unstructured":"Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellits ED, Denckla MB (1995) The treatment of attention-deficit hyperactivity disorder in Tourette\u2019s syndrome: a double-blind, placebo controlled study with clonidine and desipramine. Pediatrics 95:74\u201381","journal-title":"Pediatrics"},{"key":"979_CR103","doi-asserted-by":"crossref","unstructured":"Steeves T, McKinlay BD, Gorman D, Billinghurst L, Day L, Carroll A, Dion Y, Doja A, Luscombe S, Sandor P, Pringsheim T (2012) Canadian guidelines for the evidence-based treatment of tic disorders: behavioural therapy, deep brain stimulation, and transcranial magnetic stimulation. Can J Psychiatry 57:144\u2013151","DOI":"10.1177\/070674371205700303"},{"key":"979_CR104","doi-asserted-by":"crossref","unstructured":"Verdellen C, van de Griendt J, Hartmann A, Murphy T, ESSTS Guidelines Group (2012) European clinical guidelines for Tourette syndrome and other tic disorders. Part III: behavioural and psychosocial interventions. Eur Child Adolesc Psychiatry 20:197\u2013207","DOI":"10.1007\/s00787-011-0167-3"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-0979-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-013-0979-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-013-0979-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T00:47:03Z","timestamp":1687999623000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-013-0979-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,30]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["979"],"URL":"https:\/\/doi.org\/10.1007\/s00702-013-0979-z","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,30]]}}}